At STAT's Breakthrough Summit East, the CEOs of Ro and Included Health said the the U.S. health care system poses obstacles ...

Novo Nordisk A/S (NYSE: NVO) has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are ...

Novo Nordisk stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its next-generation GLP ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

The company’s groundbreaking GLP-1 receptor agonists have revolutionized the management of these chronic conditions, propelling Novo Nordisk to new heights in the pharmaceutical industry.

Novo Nordisk (NYSE: NVO), the Danish company best known as the maker of weight loss drug Wegovy, expanded a little on the ...

Allurion Technologies' gastric balloon and Novo Nordisk's semaglutide achieved 20.3% weight loss in a trial. Read more here.

A class action lawsuit was filed against Novo Nordisk A/S (NVO) by Levi & Korsinsky on January 24, 2025. The plaintiffs ...

The company’s groundbreaking GLP-1 receptor agonists have revolutionized the management of these chronic conditions, propelling Novo Nordisk to new heights in the pharmaceutical industry. As the ...

Novo Nordisk A/S NVO has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are no longer in short supply. This caused the United States Food and Drug ...